THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
20 déc. 2017 08h45 HE | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
09 nov. 2017 08h45 HE | Abeona Therapeutics Inc.
Company Opens European Subsidiary in Spain to Support Global Clinical DevelopmentNine subjects at global clinical sites enrolled to date with more than 2,000 days cumulative follow up assessed NEW...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
06 oct. 2017 08h25 HE | Abeona Therapeutics Inc
--Demonstrated durable and significant reduction of underlying disease pathology across multiple clinical measures in Cohort 1 (n=3) compared to controls (n=8-12) --Systemic Biopotency demonstrated...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
28 sept. 2017 08h32 HE | Abeona Therapeutics Inc
--Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation --Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Upcoming Conference Participation
22 sept. 2017 08h45 HE | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017
17 août 2017 09h15 HE | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A
16 août 2017 09h25 HE | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies...
Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer
25 juil. 2017 08h05 HE | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, July 25, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona to Present At Multiple Upcoming Conferences
20 avr. 2017 08h05 HE | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, April 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Announces Rare Disease Gene Therapy Symposium with the New York Academy of Sciences
05 avr. 2017 07h43 HE | Abeona Therapeutics Inc
Company CEO to Co-Chair Symposium being held on April 11th in NYC NEW YORK and CLEVELAND, April 05, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage...